SEATTLE, Nov. 8, 2022
/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced
that management will provide a corporate overview at two upcoming
investor conferences in New York
and London.
Presentation details:
Event: Stifel Healthcare Conference
Date: Tuesday, November 15, 2022
Time: 1:15 p.m. ET
Event: Jefferies London Healthcare Conference
Date: Thursday, November 17, 2022
Time: 10:50 a.m. ET/3:50 p.m. GMT
Both presentations will be webcast live and available for replay
from the Investors section of CTI BioPharma's website at
www.ctibiopharma.com.
About CTI BioPharma
Corp.
We are a commercial biopharmaceutical company focused on the
acquisition, development and commercialization of novel targeted
therapies for blood-related cancers that offer a unique benefit to
patients and their healthcare providers. CTI has one FDA-approved
product, VONJO® (pacritinib), a JAK2 and IRAK1
inhibitor, that spares JAK1. VONJO is approved for the treatment of
adults with intermediate- or high-risk primary or secondary
(post-polycythemia vera or post-essential thrombocythemia)
myelofibrosis with a platelet count below 50 × 109/L.
This indication is approved under FDA accelerated approval based on
spleen volume reduction. Continued approval for this indication may
be contingent upon verification and description of clinical benefit
in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA
study of VONJO in patients with myelofibrosis and severe
thrombocytopenia as a post-marketing requirement.
VONJO® is a registered trademark of CTI BioPharma
Corp.
CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-upcoming-november-conferences-301671331.html
SOURCE CTI BioPharma Corp.